Key result
TAK-242 improves cardiac function and attenuates remodeling by blocking cardiomyocyte pyroptosis in diabetic cardiomyopathy.
Why the study?
Diabetic cardiomyopathy is a progressive disease leading to heart failure, and Toll-like receptor signaling is believed to be implicated in its pathogenesis.
Does TLR4 inhibition with TAK-242 alleviate diabetic cardiomyopathy and inhibit cardiomyocyte pyroptosis via the TLR4/CaMKII/NLRP3 pathway in diabetic rats and high-glucose-stimulated H9c2 cells?
Does TLR4 inhibition with TAK-242 alleviate diabetic cardiomyopathy and inhibit cardiomyocyte pyroptosis via the TLR4/CaMKII/NLRP3 pathway in diabetic rats and high-glucose-stimulated H9c2 cells?
In preclinical rat and cell models of diabetic cardiomyopathy, the selective TLR4 inhibitor TAK-242 improved cardiac function, attenuated hypertrophy and fibrosis, and suppressed cardiomyocyte pyroptosis by inhibiting the downstream CaMKII/NLRP3 signaling pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for TLR4 inhibition in diabetic cardiomyopathy; leaves open translation to human disease.
Diabetic cardiomyopathy (DCM) is identified as a progressive disease that may lead to irreparable heart failure. Toll-like receptor (TLR) signaling is believed to be implicated in the pathogenesis of DCM. This study intended to explore the potential impact of Toll-like receptor 4 (TLR4) on DCM in vitro and in vivo . Streptozotocin and HG medium were utilized to induce diabetes in animal and cell models, respectively. Selective TLR4 inhibitor TAK-242 and calcium/calmodulin-dependent protein kinase-II (CaMKII) inhibitor KN-93 were employed to explore the involvement of TLR4/CaMKII in DCM. TLR4 expression was increased in DCM hearts, while inhibition of TLR4 activation by TAK-242 improved cardiac function, attenuated heart hypertrophy, and fibrosis, as well as reduced oxidative stress and proinflammatory cytokine levels in rats, which were confirmed by Doppler echocardiography, hematoxylin and eosin staining, and Masson Trichome staining and specific enzyme-linked immunosorbent assay kits. Besides, the expression of hypertrophy-related molecules and oxidative stress damage were also inhibited by TAK-242. Furthermore, TAK-242 treatment reduced CaMKII phosphorylation accompanied by decreased expression of NOD-like pyrin domain-containing protein 3, gasdermin D (GSDMD), The N-terminal domain of Gasdermin D (GSDMD-N), apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) and Caspase-1 both in vivo and in vitro. Similar positive impacts on HG-induced pyroptosis were also observed with KN-93 treatment, and this was achieved without affecting TLR4 expression. Collectively, our work suggested that TAK-242 demonstrated substantial benefits against DCM both in vivo and in vitro , potentially attributed to the suppression of the TLR4-mediated CaMKII/NLRP3 pathway activity.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) studied Diabetic cardiomyopathy (DCM) (n=40). TAK-242 (selective TLR4 inhibitor) and KN-93 (CaMKII inhibitor) vs. Vehicle (DMSO / citrate buffer) in diabetic and control groups was evaluated on Cardiac function (EF, FS, E/A ratio, LVIDs), hypertrophy, fibrosis, and cardiomyocyte pyroptosis via TLR4/CaMKII/NLRP3 signaling (p=<0.05). TAK-242 improved cardiac function, attenuated cardiac hypertrophy and fibrosis, and inhibited cardiomyocyte pyroptosis via the TLR4/CaMKII/NLRP3 pathway in diabetic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: